The concept of singularity has a number of definitions, including those deriving from astrophysics and mathematics.
However, it is now most commonly used in the sense popularised by Ray Kurzweil, namely to denote ‘a unique event with singular implications’.
As a proper noun, Kurzweil’s Singularity reflects on the numerous ‘implications of the fact that the rate of [technological] change itself is accelerating’:
We won’t experience one hundred years of technological advance in the twenty-first century; we will witness in the order of twenty thousand years of progress when measured by today’s  progress, or about one thousand times greater than that which was achieved in the twentieth century.
The implications of the fifth epoch of evolution Kurzweil envisages wherein technology and human intelligence merge are both monumental and, value judgments aside, apparently inevitable.
It seems inadequate to address these impacts in terms of the effect that they will have on our existing state of economic arrangements on the basis that the latter have never appeared more likely to prove unsustainable and self-destructive.
In an era in which such superlatives as ‘game-changing’, ‘disruptive’, and ‘revolutionary’ are wantonly abused and in reality seldom signify anything other than ‘accretion described excitedly’, it is hardly appropriate to attempt to further categorise the impact of the technological determinism Kurzweil identifies so compellingly.
Whilst it now appears self-evident that primary care will be first supplemented then replaced by an omniscient AI, before and after the Singularity arrives in 2045 (according to a surprisingly confident Kurzweil) we are all going to need medicines.
Who will be providing them?
A legacy pharmaceutical industry that is compelled to submit to the punctilious will of regulators in environments that cannot be regulated?
A legacy pharmaceutical industry that can neither anticipate nor adequately respond to the challenges posed by new entrants?
A legacy pharmaceutical industry that remains wary of communicating with the people who use its products?
The very survival in its legacy form of an industry so slow to reform itself may be in doubt.
The pharma Singularity is near, and on the basis of the evidence that we have to hand, it appears it will be arriving a good deal sooner than 2045.